BMRN - Biomarin Pharmaceutical Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMRN - Biomarin Pharmaceutical Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (12)	1/11/2009 7:09:13 PM
From: ghmm	Read Replies (1) of 18

Didn't realize there was a Board here. Good to see. Did hear anything about a buzz from the presentation at American Society Hematology Meeting? I think either way the program won't go forward till their is more clarity on their BH4 program in general. In Q1 there will be results in PAD, PAH, Proteinuria, Chronic Kidney disease. If none of those show promise I would imagine they proceed with the current BH4 molecule (Kuvan) in Sickle Cell (I think they'ld do a blinded Phase 2) and perhaps more slowly develop the BH4 Prodrug since both would be orphan indications. Just speculating :)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next